GSK Advances Nucala for COPD Approval

GSK plc recently announced that the U.S. FDA has accepted data from the MATINEE study to support the regulatory review for Nucala (mepolizumab) as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This submission is based on the efficacy and safety results from the MATINEE study, which included 804 patients and showed a significant reduction in the annualized rate of moderate/severe exacerbations when mepolizumab was added to inhaled maintenance therapy.

The study demonstrated that mepolizumab significantly reduced exacerbations and showed a clinically meaningful improvement in COPD management. IL-5, a key cytokine in type 2 inflammation, is central to the pathophysiology of COPD in up to 40% of patients, and mepolizumab targets this cytokine. The MATINEE study also included patients with diverse COPD presentations, including emphysema-only and chronic bronchitis-only subgroups.

COPD is a major global health issue, affecting over 390 million people worldwide and over 14 million in the U.S. The disease exerts a significant burden on healthcare systems, with frequent exacerbations being a primary cause of hospitalization. The approval of mepolizumab for COPD could provide a new treatment option for patients who experience these severe exacerbations.

Currently, Nucala is approved for use in the U.S. for four IL-5 mediated conditions, including severe asthma with eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. However, Nucala is not yet approved for COPD in any market, and the MATINEE study data will form the basis for future regulatory submissions globally. The PDUFA date for the FDA's review of Nucala for COPD is set for May 7, 2025.